Loading candles…
SMS Pharmaceuticals Ltd, incorporated in 1989 and headquartered in Hyderabad, India, operates as a diversified and vertically integrated pharmaceutical company. It specializes in the development and manufacturing of Active Pharmaceutical Ingredients (APIs) and complex intermediates. The company serves the pharmaceutical industry with a focus on business segments including APIs and intermediates. SMS Pharmaceuticals has a notable presence in regulated markets, which accounted for 88% of its revenue in fiscal year 2025. It exports its products to over 75 countries worldwide. The company holds leadership positions in therapeutic areas such as anti-diabetic and anti-inflammatory products. There are no listed subsidiaries, founders, or key management details available for SMS Pharmaceuticals Ltd.
| Results - FY25 |
| To consider and approve the financial results for the period ended December 31, 2025 and other business matters |
| 7 Feb 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended September 30, 2025 and other business matters | 8 Nov 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 and other business matters | 9 Aug 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended March 31, 2025, dividend and other business matters | 30 May 2025 |
Besseggen InfoTech LLP is a SEBI-registered stock broker (Reg. No. INZ000213450), member of NSE (90155 (Cash & F&O)) and BSE (6722 (Cash & F&O)). Investment in securities market are subject to market risks; read all related documents carefully before investing.